PW Medtech acquires Chinese medical device peer; FDA approves brain function analysis system;

@FierceMedDev: ICYMI yesterday: Home healthcare design considerations addressed in FDA final guidance. Story | Follow @FierceMedDev

@StacyALawrence: Philips, Accenture create brain wave app for immobilized patients. Article | Follow @StacyALawrence

@VarunSaxena2: Stentys ditches bare metal stents as customers move to drug-eluting versions. FierceDrugDelivery story | Follow @VarunSaxena2

@MichaelGFierce: Thin and strong, graphene sheets form spheres spontaneously for drug release. Story | Follow @MichaelGFierce

@EmilyWFierce: Quick point-of-care devices could be the next "holy grail" in detecting infectious diseases like Ebola. More from NBC News | Follow @EmilyWFierce

> Chinese medical device company PW Medtech Group acquired Beijing Lima Tianxinfu Medical Devices for 802.6 million RMB ($130.1 million). Release

> The FDA gave its approval for ElMindA's non-invasive brain function BNA Analysis System. Release

> SynCardia Systems' Total Artificial Heart received FDA approval, giving the company the go-ahead on both their unique heart valves and segmented polyurethane solution. Release

> Oxford Immunotec acquired rheumatology and infectious disease-concentrated company Boulder Diagnostics for $7.9 million. Release

Biotech News

@FierceBiotech: New special report: The top 15 late-stage blockbusters in the pipeline. Feature | Follow @FierceBiotech

@JohnCFierce: ICYMI yesterday: How big is Novartis's LCZ696 heart drug? Experts bet on a key number. Article | Follow @JohnCFierce

@DamianFierce: Auris Medical prices $56M IPO, ushers in the era of $EARS on Wall Street. Release (PDF) | Follow @DamianFierce

> Regeneron hits the gas on R&D, pouring cash into a blockbuster pipeline. More

> Auris pulls off a $56M IPO to bankroll its ear treatments. Report

> Sarepta leaps into Ebola spotlight with a shelved therapy. Story

> Cytori shares slammed as safety concerns halt stem cell trials. Article

Pharma News

@FiercePharma: Best-read news yesterday: Express Scripts hits Amgen, Zogenix as it punts another 25 drugs. Story | Follow @FiercePharma

@TracyStaton: Tops @FiercePharma over the weekend: Top Sanofi exec departs amid struggles in diabetes franchise. Report | Follow @TracyStaton

@EricPFierce: Novartis hangs 'For Sale' sign on U.S. plant as it prepares to close and sell facility and lay off 500. FiercePharmaManufacturing story | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: Ackman's crusade for Valeant-Allergan combo gets a key nod from proxy advisers. Report | Follow @CarlyHFierce

> AbbVie decides against Supreme Court appeal for ruling that extended rights to gays. More

> Zogenix seeks partner, steers Zohydro marketing away from weak New England. Story

> UCB hops on pharma's spinoff wagon with potential $2B sale of generics business. Article

Drug Delivery News

> BD launches AutoShield Duo pen for diabetics. Report

> BioDelivery Sciences International to add 80 patients to clinical trial of Clonidine Topical Gel. Item

> Carnegie Mellon team creates self-assembling nanofibers for shaped delivery vehicles. Article

> Biodegradable film strip enabling 14 months of drug delivery prototyped by MIT team. Story

> Stentys ditches bare metal stents as customers move to drug-eluting versions. Article

Diagnostics News

> Johns Hopkins group scrutinizes possible biomarker for suicide risk. News

> Dx industry is cautious, wary and diplomatic in the face of FDA's push to regulate LDTs. Report

> MGC Diagnostics completes Belgian M&A deal with an eye on globalization. More

> Exosome Diagnostics replaces CEO and relocates as it preps for commercialization. Article

> OncoCyte rolls out massive trial for bladder cancer Dx. Story

Pharma Marketing News

> Third to market may still be a charm for Lilly, BI's new diabetes med Jardiance. More

> GSK relaunches COPD patient site with blockbuster sales on the line. Item

> The formularies are here! Brace yourselves for the 48 new exclusions. Report

> J&J Baby aims to turn ingredients scandal into sales with 'transparent' ad campaign. Story

> Teva eyes 'hard switch' to hit Copaxone goals if the soft sell isn't enough. Article

Suggested Articles

Qiagen launched a one-stop shop compiling publicly available genomic data, scientific literature and phenotypic information on potential superbugs.

Adaptive Biotechnologies is planning a $200 million IPO to help power its sequencing tests aimed at the body’s immune system and related therapies.

Abbott’s new diabetes test provides A1c results in three minutes, allowing clinicians to develop care plans within a single office visit.